Evidence map›Paper›PMID 42375918›Full record

ArticleCureus2026

Impact of Poor Adherence to Treatment on Recurrent Disease Activity in Pemphigus Foliaceus: A Case Report.

Luisa F Vazquez Enriquez, Kenia Dominguez Romo, Jose M Hurtado Cordova

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Luisa F Vazquez EnriquezInternal Medicine, Hospital General de Zona No. 33, Instituto Mexicano del Seguro Social, Monterrey, MEX.
Kenia Dominguez RomoInternal Medicine, Hospital General de Zona No. 33, Instituto Mexicano del Seguro Social, Monterrey, MEX.
Jose M Hurtado CordovaInternal Medicine, Hospital General de Zona No. 33, Instituto Mexicano del Seguro Social, Monterrey, MEX.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pemphigus foliaceus is a rare autoimmune blistering disease characterized by superficial intraepidermal blister formation and chronic relapsing disease activity. Although systemic immunosuppressive therapy remains the cornerstone of treatment, adherence to both systemic and topical therapies may influence disease control, skin barrier integrity, and susceptibility to secondary infections. We present the case of a 73-year-old man with a history of hypertension, type 2 diabetes mellitus, and chronic ischemic heart disease who developed pemphigus foliaceus confirmed by clinical and histopathological findings. The disease initially manifested with vesicles and flaccid bullae involving the face and chest that progressed to erosions with serohematic crusts. The patient initially received systemic corticosteroids, antihistamines, and topical therapy without adequate response, requiring hospitalization and treatment with intravenous immunoglobulin. Therapy was later adjusted to include mycophenolic acid and corticosteroid tapering, achieving partial clinical improvement. During follow-up, the patient experienced multiple relapses associated with inconsistent adherence to topical therapy and unsupervised discontinuation of systemic corticosteroids. Despite reintroduction of immunosuppressive therapy, intermittent cutaneous activity persisted. On his final hospital admission, he developed secondary cutaneous and urinary infections caused by

Indexed as

adherenceautoimmune blistering diseasecase reportimmunosuppressive therapypemphigus foliaceusseptic shockskin infectiontopical therapy

Identifiers

PMID42375918
PMCPMC13313052

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.